Anavex Life Sciences Corp (FRA:12X1)
€ 3.495 0.164 (4.92%) Market Cap: 299.15 Mil Enterprise Value: 165.79 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 34/100

Anavex Life Sciences Corp to Review ANAVEX®2-73-AD-004 Alzheimer's Disease Phase 2b/3 Call Transcript

Dec 05, 2022 / 01:30PM GMT
Release Date Price: €11.23 (-8.92%)
Clint Tomlinson
Anavex Life Sciences Corp. - VP of Corporate

Good morning, everyone, and welcome to the ANAVEX 2-73 blarcamesine AD-004 Phase IIb/III Clinical Study Results Review Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. (Operator Instructions) Finally, note that this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com.

With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Dr. Ed Hammond, Chief Medical Officer.

Also with us are 2 distinguished professors with backgrounds in Alzheimer's disease. From the University of Texas, Professor George Perry, PhD, is Dean of Sciences and Professor of Biology at the University of Texas at San Antonio. He is a former President for the American Association of Neuropathologists and the Editor-in-Chief of the Journal of Alzheimer's Disease as well as the editorial board of over 150 other journals. Professor Perry has no affiliation with Anavex Life Sciences.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot